Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features.

Dolkar, Tsetan et al.·Journal of cutaneous pathology·2018·
RPEP-036492018RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Key Numbers

How They Did This

Why This Research Matters

What This Study Doesn't Tell Us

Trust & Context

Original Title:
Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features.
Published In:
Journal of cutaneous pathology, 45(7), 539-544 (2018)
Database ID:
RPEP-03649

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-03649·https://rethinkpeptides.com/research/RPEP-03649

APA

Dolkar, Tsetan; Trinidad, Celestine M; Nelson, Kelly C; Amaria, Rodabe N; Nagarajan, Priyadharsini; Torres-Cabala, Carlos A; Ivan, Doina; Prieto, Victor G; Tetzlaff, Michael T; Curry, Jonathan L; Aung, Phyu P. (2018). Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features.. Journal of cutaneous pathology, 45(7), 539-544. https://doi.org/10.1111/cup.13262

MLA

Dolkar, Tsetan, et al. "Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features.." Journal of cutaneous pathology, 2018. https://doi.org/10.1111/cup.13262

RethinkPeptides

RethinkPeptides Research Database. "Dermatologic toxicity from novel therapy using antimicrobial..." RPEP-03649. Retrieved from https://rethinkpeptides.com/research/dolkar-2018-dermatologic-toxicity-from-novel

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.